Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ

Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ aliu Thu, 10/10/2024 - 17:02